Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial

DSpace Repository

Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial

Author: Rohde, Gernot; Stenglein, Stephan; Prozesky, Hans; Manudhane, Ganesh; Sandulescu, Oana; Bauer, Martin; Overend, Tim; Koch, Winfried; Neuschwander, Dennis; Planz, Oliver; Torres, Antoni; Witzenrath, Martin
Tübinger Autor(en):
Planz, Oliver
Published in: Eclinicalmedicine (2023), Bd. 65, Article 102237
Verlagsangabe: Amsterdam : Elsevier
Language: English
Full text: http://dx.doi.org/10.1016/j.eclinm.2023.102237
ISSN: 2589-5370
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)